MARKET

SPRB

SPRB

Spruce Biosciences, Inc.
NASDAQ
87.11
+4.44
+5.37%
After Hours: 86.32 -0.79 -0.91% 18:31 12/31 EST
OPEN
82.00
PREV CLOSE
82.67
HIGH
87.70
LOW
81.30
VOLUME
29.42K
TURNOVER
--
52 WEEK HIGH
240.00
52 WEEK LOW
4.275
MARKET CAP
93.24M
P/E (TTM)
-1.0292
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SPRB last week (1222-1226)?
Weekly Report · 12/29/2025 09:30
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 12/23/2025 14:47
Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls
TipRanks · 12/23/2025 14:35
SPRUCE BIOSCIENCES INC <SPRB.O>: OPPENHEIMER INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $283
Reuters · 12/23/2025 13:20
BUZZ-Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength 
Reuters · 12/23/2025 13:12
Spruce Biosciences (SPRB) Initiated with a Buy at Oppenheimer
TipRanks · 12/23/2025 12:55
Spruce Biosciences Price Target Announced at $283.00/Share by Oppenheimer
Dow Jones · 12/23/2025 11:52
Oppenheimer Initiates Coverage On Spruce Biosciences with Outperform Rating, Announces Price Target of $283
Benzinga · 12/23/2025 11:41
More
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.

Webull offers Spruce Biosciences Inc stock information, including NASDAQ: SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.